TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC

Boris Guiu*, Etienne Garin, Carole Allimant, Julien Edeline, Riad Salem

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly used staging system for hepatocellular carcinoma (HCC) in Western countries. BCLC aims to categorize patients into five stages with different prognoses and to allocate treatment according to these stages based on the best possible contemporary evidence. Transarterial radioembolization (TARE) has recently entered at the left of the BCLC algorithm (i.e., BCLC 0-A), mainly because of negative phase III trials in BCLC C stage. TARE has shown a steady increase in nationwide studies over the past 20 years and has even been adopted in some tertiary centers as the primary HCC treatment across all BCLC stages. We aimed to review the history of TARE in HCC, starting from advanced HCC and gradually expanding to earlier stages at the left of the BCLC system.

Original languageEnglish (US)
JournalCardiovascular and Interventional Radiology
DOIs
StateAccepted/In press - 2022

Keywords

  • Dosimetry
  • Liver cancer
  • Radioembolization
  • Yttrium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC'. Together they form a unique fingerprint.

Cite this